News and Media
MMS HOLDINGS EXECUTIVE MICHELLE GAYARI JOINS ADVISORY BOARD OF INTERNATIONAL NONPROFIT THAT PROVIDES EDUCATIONAL PROGRAMS TO CHILDREN IN HOSPITALS
CANTON, Mich. (October 23, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced today that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501(c)(3) charity Together Educating All Children in Hospitals (TEACH). As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.
MMS HOLDINGS ANNOUNCES STATUS AS A FINALIST FOR BEST CONTRACT RESEARCH ORGANIZATION – SPECIALIST PROVIDERS IN SCRIP AWARDS DURING 10TH ANNUAL SCIENTIFIC SYMPOSIUM
CANTON, Mich. (October 10, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced its recognition as a finalist in the highly-esteemed, global Scrip Awards by Informa Pharma Intelligence as Best Contract Research Organization – Specialist Providers at the 10th Annual MMS Scientific Symposium.
CANTON, Mich. (September 30, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – celebrated another successful collaboration with Oracle Health Sciences and a specialized Oncology pharmaceutical company. MMS will share their learnings with peers at the Society for Clinical Data Management (SCDM) annual meeting in Baltimore, Md.
MMS HOLDINGS NAMED HONORABLE MENTION IN PRESTIGIOUS PR DAILY CORPORATE SOCIAL RESPONSIBILITY AWARDS FOR #ONEMMS VOLUNTEER INITIATIVE
CANTON, Mich. (September 10, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – was recently announced as an honorable mention recipient of PR Daily’s Corporate Social Responsibility Awards in the Engagement & Communications category for its #OneMMS volunteer campaign.
MMS Holdings and Sage IT Celebrate 10-Year Relationship with Deep Focus on Intelligent Automation and Bot Development
CANTON, Mich. and FRISCO, Texas (August 1, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced that today marks 10 years of successful partnership with Sage IT—a premier provider, helping companies operationalize their vision through the enhancement or development of innovative technology solutions.
MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers
CANTON, Mich. (June 27, 2019) – MMS announced today the launch of Automatiqc™ (pronounced: automatic). Automatiqc is a new cloud-based application that automatically performs quality control (QC) and style checks for medical writing, pharmacovigilance, clinical trial transparency, and other types of documents in the pharmaceutical, biotechnology, and medical device industries.
SEATTLE (May 23, 2019) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today the addition of Dr. Mike Poole, MD, FACP to its board of scientific advisors. Currently a venture partner at Biomatics Capital, Inc., Dr. Poole has more than 25 years of experience in the pharmaceutical industry, most recently having led external investments in the Office of the President for Global Health at the Bill and Melinda Gates Foundation.
MMS Holdings Leverages Medrio to Accelerate Clinical Trial Process for Study Sponsors Through New Contract
SAN FRANCISCO (May 8, 2019) – MMS Holdings – an award-winning, data-focused contract research organization (CRO) – has successfully leveraged the support services provided by Medrio, the leading provider of eClinical technology for small to mid-sized pharmaceutical companies, to execute a clinical trial sponsor agreement.
Staffordshire, United Kingdom (March 13, 2019) – GHP Magazine has awarded MMS Holdings Most Outstanding Global CRO in the 2019 Biotechnology Awards.
BREAKING NEWS: MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective
by MIT news, January 25, 2019
The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory aims to significantly shorten the approval process for pharmaceutical and health care groups.